Lilly scurries to get out from under Zyprexa cloud
Another year of rapid change at Eli Lilly and Co. did little to move the company out from under the cloud cast by its best-selling
drug, Zyprexa.
Eli Lilly and Co.
Articles
Lilly pays $90 million for autoimmune drug
By acquiring an experimental medicine for rheumatoid arthritis, the Indianapolis-based drugmaker is increasing its focus on autoimmune
diseases.
Senate rejects drug-importation proposal
The U.S. Senate voted down a plan Tuesday to allow Americans to import prescriptions from abroad, handing drug makers
such as Indianapolis-based Eli Lilly and Co. a victory.
Lilly wins approval for long-acting Zyprexa
Once-a-month injection of best-selling drug will have patents that could extend until 2018.
Lilly charity gives $1M to new IU health school
The Eli Lilly and Co. Foundation has given Indiana University $1 million to start a school of public health at Indiana University-Purdue
University Indianapolis.
Eli Lilly’s shares slip after it forecasts mixed profits in coming years
The Indianapolis-based drugmaker predicts strong profits through 2011, but its forecast for 2012 suggests bottom-line results
could fall precipitously.
Lilly launching new venture capital fund
The fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly’s drug pipeline.
Lilly forecasts growth in earnings next year
Eli Lilly and Co. said it still expects its earnings per share to grow in the double-digit range through 2011.
Ariad asks court to restore patent-suit win against Lilly
A federal appeals court will decide whether Eli Lilly and Co. must pay $65.2 million in damages, plus royalties, over a drug-patent
claim.
Builder looks to cold storage for steady work in a weak economy
Cold storage might become a hot business for a building contractor.
Part of Mississippi’s Zyprexa case against Lilly dismissed
Indianapolis-based Eli Lilly and Co. has won a bid to dismiss part of a negligence lawsuit brought by Mississippi that alleges
improper marketing of antipsychotic drug Zyprexa for unapproved uses.
Lilly extends research pact with India firm
Jubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five
years.
Lilly’s Cymbalta wins new approval for anxiety disorder
FDA action should boost sales of the Eli Lilly and Co. drug, which were already on pace to top $3 billion this year.
Lilly snags talent kudos
Fortune magazine ranked the drug company among the best in the world for managing talent.
Lilly stock droops after rival claims faster-acting impotence pill
California-based Vivus claims its drug acts in 30 minutes, compared with about 2 hours for Lilly’s Cialis.
Lilly to pay Utah $24 million to settle Zyprexa suit
Eli Lilly and Co. has agreed to pay Utah $24 million to settle a lawsuit claiming the company improperly marketed the antipsychotic
drug Zyprexa.
Lilly, WellPoint CEOs pin hopes on Senate
Drugmaker and health insurer bemoan aspects of House health reform bill and hope Senate crafts more industry-friendly bill.
Lilly reducing sales force by 191 as part of larger restructuring
Eli Lilly and Co. has notified the state that it plans to eliminate 191 sales jobs as part of a company-wide restructuring
announced
in September
that ultimately will result in 5,500 job cuts by the end of 2011.
Health care businesses at risk in House proposal
The health care overhaul bill produced by House Democrats would impose an array of new taxes, fees and government mandates
on major players in the health industry, including drug companies and big medical-device makers headquartered in Indiana.
Lilly opens new biotech center in San Diego
Lilly is opening the San Diego biotech center a year after launching a biotech R&D center in Indianapolis.